Buy & Sell KKR & Co Inc (KKR) – KKR & Co Inc Price Today
Aura AI Summary
Key Stats
- $83.86BMarket Cap
- FinancialsSector
- -14.53%3M Drawdown
- $9.38BEnterprise Value
- 0.8%Dividend Yield
- 54 daysTypical Hold Time
KKR & Co Inc (KKR) is currently valued at a market capitalization of $83.86B, with an enterprise value of $9.38B. Over the past 52 weeks, KKR & Co Inc has traded between a low of $83.88 and a high of $152.16, highlighting its annual price range. Over the past three months, KKR & Co Inc has recorded a drawdown of -14.53%, reflecting recent price volatility. KKR & Co Inc offers a dividend yield of 0.8%, with the most recent dividend of $0.20 paid on 15 May 26. On average, investors hold KKR & Co Inc for approximately 54 days, indicating typical investor behavior on the platform.
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Most Recent News
Digital Realty launches Malaysia data center operations to boost Southeast Asia's digital and AI infrastructure.
Digital Realty has officially launched its Malaysia operations with a new data center campus in Cyberjaya, aiming to expand its capacity to 32 MW. This development integrates Malaysia into Digital Realty's global network, supporting AI and data-drive...
Amcor offers 7% dividend yield with 28% upside potential amid volume recovery and synergy gains.
Amcor's shares have declined nearly 9% in the first half of the year, pushing its dividend yield close to 7%, making it an attractive investment opportunity. Despite volume declines following its acquisition of Berry, the company expects recovery by ...
Novartis to present key Phase III data on Rhapsido for chronic urticaria and food allergy at EAACI 2026.
Novartis will showcase results from multiple clinical trials of Rhapsido (remibrutinib) at the EAACI Congress 2026, including pivotal Phase III data for chronic inducible urticaria and extension data for chronic spontaneous urticaria. The presentatio...